Skip to content
drillr.ai

CBIO

Crescent Biopharma, Inc.

NASDAQ · USHealthcareBiotechnology
$15.05+2.03%

Price as of Jul 20, 2026

CBIO news

Crescent Biopharma, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that it has closed its previously announced underwritten public offering of 9,387,896 ordinary shares, including 1,293,103 ordinary shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, and in lie

    Globe Newswire ·

  2. Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

    WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the pricing of its underwritten public offering of 8,094,793 ordinary shares and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. The ordinary shares are being sold to the public at

    Globe Newswire ·

  3. Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

    WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that it has commenced an underwritten public offering of its ordinary shares or, in lieu of ordinary shares to investors that so choose, pre-funded warrants to purchase its ordinary shares. In addition, Crescent intends to grant the underwriters

    Globe Newswire ·

  4. Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma (https://www.globenewswire.com/Tracker?data=1lb3vUSK3y-K2qs3zWonpK4Jy0MBQliexusJAsY9F-sptOAp8N4CMLOi8HiZbD58meK7RH-265rkRRcOuOYg7PXjXUyQulyua6tTLvAJ0QL0OdH0_8EBMikz2E464r9VNmDNcx0tjXiWYywLg47Elb0JfncQczBtYw6GZZlDtdH7Ojj5-tTqq-hMc6Et6DCxCbcQ7qiI-KQq7ejchWjAhQ_JZj1e04aewxN_udALjXrJnzmRuZlBmohKmWeDkOFldNKxYh5IRBxAjJFewBlpCQ==), Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to r

    Globe Newswire ·

  5. Crescent Biopharma to Present at June Investor Conferences

    WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (https://www.globenewswire.com/Tracker?data=Lcq6omn9jXePHdZ-8-IB4JEsJZFej-yEjdA2mo5mO38ZenWg_3XXR1-Nbw9PUkOJbWD3FfRJE_7DwKrDotqhwQK4CbHtAPzd-l4fp5obt0-hWMvHHvdM7iXhkIXKAwSE) (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor confe

    Globe Newswire ·

  6. Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

    ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical data readouts anticipated beginning in Q1 2027 Waltham, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (https://www.globenewswire.com/Tracker?data=6AKQscSUv7oDgQjpsvZvNlRNDSYA4umBfQWHalXJrC3Vwn9gX7wU5VUCd5L04cQGt4Xrmg9ofuLGXNdSwck84tcj_nMUOwXAQbtUbQHf42qQLbgxZY

    Globe Newswire ·